Protocol Review and Monitoring System (PRMS) The conduct of cancer clinical trials is central to the scientific mission of the University of Arizona Cancer Center (UACC). The development and implementation of a broad portfolio of cancer trials requires an extensive institutional commitment of scientific, operational, and patient resources; thus, oversight of the scientific merit and progress of the trial portfolio is paramount in ensuring that trial outcomes help shape the future of cancer prevention and treatment. The internal oversight of the scientific aspects of all cancer trials and the monitoring of the progress of cancer trials research is managed by the UACC Protocol Review and Monitoring System (PRMS). The Scientific Review Committee (SRC) serves as the principal functional component of the PRMS; it is the chartered, multidisciplinary body charged with the ultimate review of the scientific merit, prioritization, and progress of all cancer trials proposed by UACC Principal Investigators, with the exception of those trials that have undergone external peer-review through NIH and its funding agencies. The SRC membership is composed of a broad spectrum of specialists in cancer treatment, cancer prevention, therapeutic development, and basic and population science that mirrors the breadth of the UACC's clinical trial portfolio. Cancer trials are risk-stratified for determination of need for full Committee versus administrative expedited review. A systematic process is in place for the monitoring of accrual to trials and of trial scientific progress. The SRC has the authority to terminate trials that have not met pre-specified accrual targets or that are not meeting their scientific objectives. The PRMS performance metrics are generated by the clinical research system OnCore and provide the basis for PRMS quality improvement initiatives.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA023074-39
Application #
9735142
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-07-01
Budget End
2020-06-30
Support Year
39
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Arizona
Department
Type
DUNS #
806345617
City
Tucson
State
AZ
Country
United States
Zip Code
85721
Hsu, Chiu-Hsieh; Yu, Mandi (2018) Cox regression analysis with missing covariates via nonparametric multiple imputation. Stat Methods Med Res :962280218772592
Agasid, Mark T; Wang, Xuemin; Huang, Yiding et al. (2018) Expression, purification, and electrophysiological characterization of a recombinant, fluorescent Kir6.2 in mammalian cells. Protein Expr Purif 146:61-68
Wales, Jessica A; Chen, Cheng-Yu; Breci, Linda et al. (2018) Discovery of stimulator binding to a conserved pocket in the heme domain of soluble guanylyl cyclase. J Biol Chem 293:1850-1864
Bell, Melanie L (2018) New guidance to improve sample size calculations for trials: eliciting the target difference. Trials 19:605
Lindeman, Leila R; Randtke, Edward A; High, Rachel A et al. (2018) A comparison of exogenous and endogenous CEST MRI methods for evaluating in vivo pH. Magn Reson Med 79:2766-2772
Remeniuk, Bethany; King, Tamara; Sukhtankar, Devki et al. (2018) Disease modifying actions of interleukin-6 blockade in a rat model of bone cancer pain. Pain 159:684-698
Goldenberg, Joshua M; Pagel, Mark D; Cárdenas-Rodríguez, Julio (2018) Characterization of D-maltose as a T2 -exchange contrast agent for dynamic contrast-enhanced MRI. Magn Reson Med 80:1158-1164
Blohm-Mangone, Karen; Burkett, Nichole B; Tahsin, Shekha et al. (2018) Pharmacological TLR4 Antagonism Using Topical Resatorvid Blocks Solar UV-Induced Skin Tumorigenesis in SKH-1 Mice. Cancer Prev Res (Phila) 11:265-278
Tao, Shasha; Rojo de la Vega, Montserrat; Chapman, Eli et al. (2018) The effects of NRF2 modulation on the initiation and progression of chemically and genetically induced lung cancer. Mol Carcinog 57:182-192
Russ, Atlantis; Hua, Anh B; Montfort, William R et al. (2018) Blocking ""don't eat me"" signal of CD47-SIRP? in hematological malignancies, an in-depth review. Blood Rev 32:480-489

Showing the most recent 10 out of 1336 publications